Written by the Nuvirox Research Team
Key Points
- A 2024 mouse study found NMN (an NAD+ precursor) reduced airway inflammation and mucus in a house-dust-mite model of allergic asthma.
- No human trial has tested NAD+ precursors specifically in people with asthma.
- A related human trial in COPD — a different, though overlapping, airway disease — found NR significantly reduced a key inflammation marker over 6 weeks, offering an adjacent (not equivalent) data point.
Short answer: promising results in mice with allergic asthma, and zero direct human asthma trials so far. There is genuinely useful adjacent human data from a related lung condition, though, and it's worth walking through both pieces honestly rather than blending them into a single answer.
The proposed mechanism
Asthma involves disruption of the airway epithelium — the barrier tissue lining your airways — along with chronic inflammation and excess mucus production. A 2024 study investigated whether restoring cellular NAD+ with nicotinamide mononucleotide (NMN) could help, testing it in a house-dust-mite-induced mouse model of allergic asthma. NMN reduced airway inflammation and mucus secretion, and helped protect the airway epithelial barrier from disruption, in a process the researchers linked to a specific protein (SIRT3) that depends on NAD+ to function.
What the adjacent human data shows — and why it's not the same disease
The most relevant human data comes from a 2024 randomized, double-blind, placebo-controlled trial in patients with stable COPD (chronic obstructive pulmonary disease) — not asthma. COPD and asthma both involve airway inflammation, but they're distinct diseases with different underlying causes (COPD is typically linked to smoking and progressive, largely irreversible airflow limitation; asthma is often allergic and more variable/reversible). In that COPD trial, 40 patients took nicotinamide riboside (NR) for 6 weeks, and the study found a significant 52.6% reduction in a key airway inflammation marker (sputum IL-8) compared to placebo — an effect that persisted at 12-week follow-up. Blood NAD+ more than doubled with treatment. Notably, a different inflammatory marker (plasma IL-6) showed no significant change, an honest limitation the study's own authors flagged.
More detail on how the COPD trial actually worked
It's worth understanding the COPD trial's design a bit more, since it's the strongest adjacent human data available. The 40 enrolled patients (mean age 71.9 years) all had a history of significant smoking (more than 10 pack-years) and a low eosinophil count, meaning this was specifically a "non-eosinophilic," typically less allergic-type inflammation profile — arguably the opposite end of the inflammatory spectrum from allergic asthma, which is usually eosinophil-and-Th2-driven. The trial also included lung-healthy control participants with no smoking or lung disease history, allowing researchers to compare baseline NAD+ differences by disease status as well as treatment response. In post-hoc analysis, the trial found a 58% reduction in sputum neutrophil count with NR treatment — neutrophils being the immune cell type most associated with COPD-type inflammation, again distinct from the eosinophils that dominate allergic asthma. This inflammatory-profile mismatch is exactly why COPD trial results, however well-conducted, can't be assumed to carry over to asthma.
How the mouse asthma mechanism is thought to work
In the 2024 NMN asthma study, the researchers identified a specific pathway: NMN treatment activated an enzyme called SIRT3 by preventing its degradation (via inhibiting a modification called SUMOylation), and SIRT3 activation reduced oxidative stress in airway epithelial cells exposed to house dust mite allergen. This is a genuinely detailed mechanistic study — the kind that often precedes human trials in a research pipeline — but a well-characterized mouse mechanism is still a different thing from a demonstrated human clinical benefit.
Why this doesn't transfer directly to a person with asthma
Even setting aside the human-vs-mouse gap, COPD and asthma have different inflammatory profiles (COPD is often neutrophil-driven; allergic asthma is often eosinophil/Th2-driven), different trigger patterns, and different treatment approaches. A trial showing benefit in one doesn't establish benefit in the other. As far as we found in the current research, no trial has enrolled asthma patients specifically to test an NAD+ precursor's effect on their symptoms, inflammation markers, or lung function. For a related discussion of NAD+ research in a third respiratory condition, see our review of NAD+ and idiopathic pulmonary fibrosis, another lung disease currently under active study.
What this means if you have asthma
Asthma management — inhaled corticosteroids, bronchodilators, and trigger avoidance — is well-established and should continue to be directed by your physician or pulmonologist. This research is worth being aware of as an area under early investigation, not as a basis for adjusting your current treatment plan, particularly since uncontrolled asthma can become a medical emergency. For a closely related, more mature body of human trial evidence, see our review of NAD+ and COPD, which covers the trial referenced above in full detail.
FROM NUVIROX
Because of the caveats above, we'd encourage you to read this as general background rather than a treatment plan. If you're curious about the ingredient at the center of this research, here's what's in ours, alongside clinician-routing guidance for anything beyond everyday support:
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol + 50 mg quercetin — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg fenugreek galactomannans to support absorption
- Backed by a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
Frequently asked questions
Can NAD+ supplements help with asthma symptoms?
There's no human trial testing this directly. The available evidence is a single mouse study using NMN, a related but distinct NAD+ precursor from the nicotinamide riboside in most NAD+ supplements.
Is asthma the same as COPD for research purposes?
No. They're distinct diseases with overlapping but different inflammatory mechanisms. A finding in COPD patients doesn't automatically apply to people with asthma.
Should someone with asthma stop their inhaler and try an NAD+ supplement?
No — asthma can become a medical emergency if undertreated, and there's no research supporting an NAD+ precursor as a substitute for standard asthma management.
Does the mouse asthma study use the same ingredient as NAD+ Restore?
It used NMN (nicotinamide mononucleotide), a related but different NAD+ precursor than the nicotinamide riboside (NR) used in NAD+ Restore and in the human COPD trial referenced here.
Were the COPD trial patients similar to typical asthma patients?
Not especially — they were older adults with a significant smoking history and a low eosinophil count, representing a less-allergic inflammatory profile than what's typical in allergic asthma, which usually involves eosinophil-driven inflammation.
What would a human asthma trial need to look like to be convincing?
Ideally, a randomized, placebo-controlled trial enrolling asthma patients specifically (not COPD patients), measuring asthma-relevant outcomes like lung function, exacerbation rate, and eosinophilic inflammation markers — the same rigorous design used in the COPD trial referenced here, just applied to the correct patient population.
The bottom line: there's a real, coherent mechanistic story here, tested convincingly in mice and partially in a related human lung disease — but not, so far, in asthma itself. That's a meaningful gap, and it's the kind of gap that deserves to stay visible rather than get smoothed over by adjacent data.
References
- Nicotinamide mononucleotide attenuates airway epithelial barrier dysfunction via inhibiting SIRT3 SUMOylation in asthma. PMID: 38064810.
- Norheim KL, et al. Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial. Nat Aging. 2024. PMID: 39548320.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.